openPR Logo
Press release

Progressive Supranuclear Palsy Treatment Market Size in the 7MM was ~USD 8.3 Million in 2022, estimated DelveInsight

08-06-2024 06:14 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Progressive Supranuclear Palsy Treatment Market

Progressive Supranuclear Palsy Treatment Market

DelveInsight's "Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the progressive supranuclear palsy historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Progressive Supranuclear Palsy Market Report
• The increase in Progressive Supranuclear Palsy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Progressive Supranuclear Palsy Market is anticipated to witness growth at a considerable CAGR.
• In 2022, the total prevalent cases of progressive supranuclear palsy were estimated to be approximately 80,706 cases in the 7MM. These cases are projected to increase during the forecast period.
• In the US, there were approximately 21,087 prevalent cases of progressive supranuclear palsy in 2022. These cases are expected to increase by 2032.
• In 2022, among the 7MM, Japan accounted for the highest prevalent cases of progressive supranuclear palsy, contributing nearly 29%, while Spain accounted for the least with nearly 7% of the total prevalent cases.
• Of the total prevalent cases of progressive supranuclear palsy in the US, around 27% were diagnosed in 2022. The cases are expected to increase at a CAGR of 1.1%.
• According to DelveInsight estimates, males are more affected with PSP than females
• The leading Progressive Supranuclear Palsy Companies such as Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Transposon Therapeutics, Oncolys Biopharma, Ferrer Asceneuron, UCB Biopharma, Novartis, and others
• Promising Progressive Supranuclear Palsy Therapies such as BRAVYL (fasudil), AZP2006 (ezeprogind), TPN-101/OBP-601 (censavudine), ASN90, NIO752, UCB0107 (bepranemab), and others

Discover which therapies are expected to grab the Progressive Supranuclear Palsy Market Share @ Progressive Supranuclear Palsy Market Outlook- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Supranuclear Palsy Overview
Progressive supranuclear palsy (PSP) is a rare neurological disorder that causes problems with balance, movement, vision, speech and swallowing. It is usually sporadic, occurs infrequently and without a known cause. The disease results in brain cells being damaged due to protein build-up which impacts parts of brain that control thinking and body movement. It is also called Steele-Richardson-Olszewski syndrome.

Progressive Supranuclear Palsy Epidemiology Insights
The epidemiology section of Progressive Supranuclear Palsy offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Prevalent cases
• Diagnosed prevalent cases
• Gender-specific cases
• Phenotype-specific cases

Download the report to understand which factors are driving Progressive Supranuclear Palsy Epidemiology trends @ Progressive Supranuclear Palsy Epidemiological Insights- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Supranuclear Palsy Drugs Market
The Progressive Supranuclear Palsy Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Progressive Supranuclear Palsy signaling in Progressive Supranuclear Palsy are likely to uncover new therapeutic targets and further expand treatment options for patients.

Progressive Supranuclear Palsy Treatment Market Landscape
The Progressive Supranuclear Palsy treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Progressive Supranuclear Palsy has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Progressive Supranuclear Palsy Market Outlook
The report's outlook on the Progressive Supranuclear Palsy market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Progressive Supranuclear Palsy therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Progressive Supranuclear Palsy drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Progressive Supranuclear Palsy market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Progressive Supranuclear Palsy Drugs Uptake
The drug chapter of the Progressive Supranuclear Palsy report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Progressive Supranuclear Palsy.

Major Progressive Supranuclear Palsy Companies
oolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Transposon Therapeutics, Oncolys Biopharma, Ferrer Asceneuron, UCB Biopharma, Novartis, and others

Scope of the Progressive Supranuclear Palsy Market Report
• Coverage- 7MM
• Progressive Supranuclear Palsy Companies- Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Transposon Therapeutics, Oncolys Biopharma, Ferrer Asceneuron, UCB Biopharma, Novartis, and others
• Progressive Supranuclear Palsy Therapies- BRAVYL (fasudil), AZP2006 (ezeprogind), TPN-101/OBP-601 (censavudine), ASN90, NIO752, UCB0107 (bepranemab), and others
• Progressive Supranuclear Palsy Market Dynamics: Progressive Supranuclear Palsy Market Drivers and Barriers
• Progressive Supranuclear Palsy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Progressive Supranuclear Palsy Drugs in development @ Progressive Supranuclear Palsy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Progressive Supranuclear Palsy Market Overview at a Glance
4. Methodology of progressive supranuclear palsy Epidemiology and Market
5. Executive Summary of progressive supranuclear palsy
6. Key Events
7. Disease Background and Overview
8. Progressive Supranuclear Palsy Patient Journey
9. Progressive Supranuclear Palsy Epidemiology and Patient Population
10. Emerging Progressive Supranuclear Palsy Drugs
11. Progressive Supranuclear Palsy Market Analysis
12. Key Opinion Leaders' Views
13. SWOT
14. Progressive Supranuclear Palsy Unmet Needs
15. Progressive Supranuclear Palsy Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimers
19. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
info@delveinsight.com
+91-9650213330

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Progressive Supranuclear Palsy Treatment Market Size in the 7MM was ~USD 8.3 Million in 2022, estimated DelveInsight here

News-ID: 3612794 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Progressive

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 - …
"The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic. The progressive multifocal leukoencephalopathy treatment market size is
Progressive Multifocal Leukoencephalopathy Treatment Market Size 2034
DelveInsight's 'Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast - 2034' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Progressive Multifocal Leukoencephalopathy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report • According to DelveInsight's analysis, the incident cases of PML in the 7MM were approximately 4
Benefits of Progressive Web App for A Business
Progressive Web Apps (PWAs) offer numerous benefits for businesses seeking to enhance their online presence and improve user experiences. Firstly, PWAs are designed to work seamlessly across various devices and platforms, including desktops, smartphones, and tablets. This cross-platform compatibility ensures that businesses can reach a wider audience without the need for separate native apps for each operating system, thereby reducing development costs and maintenance efforts. If you are planning to grow
Seminar on Progressive Farming
Shri Venkateshwara University/VGI Meerut in collaboration with Bhartiya Kisan Union (Meerut Division) is organizing a 1 day seminar on Progressive farming & farmer the foundation of development on Nov 3rd.In this seminar, the National Organization Minister of All India Farmer's Organization Mr Dinesh Kulkarni, Padamshree Mr Bharat Bhushan Tyagi, & the State Agriculture Minister Mr Baldev Singh Aulakh will take part.Apart from these renowned agriculture scientists, environmentalists, bureaucrats & 400
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability. Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and